For advanced CCA patients who refuse systemic chemotherapy or who have failed previous chemotherapy or symptomatic support, we recommend that they receive HAIC plus lenvatinib with PD-1 inhibitors. This evidence concerns the gene PDCD1 and cholangiocarcinoma.